Smith & Nephew plc (NYSE:SNN) – Research analysts at Northcoast Research raised their Q2 2019 earnings per share estimates for Smith & Nephew in a research report issued to clients and investors on Monday, February 11th. Northcoast Research analyst D. Keiser now expects that the medical equipment provider will earn $0.92 per share for the quarter, up from their prior forecast of $0.90. Northcoast Research also issued estimates for Smith & Nephew’s Q1 2020 earnings at $0.00 EPS, Q2 2020 earnings at $0.98 EPS, Q3 2020 earnings at $0.00 EPS, Q4 2020 earnings at $1.20 EPS and FY2020 earnings at $2.18 EPS.
Several other equities research analysts have also commented on the company. Morgan Stanley upgraded Smith & Nephew from an “equal weight” rating to an “overweight” rating in a research note on Monday, December 10th. HSBC lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Zacks Investment Research lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. JPMorgan Chase & Co. lowered Smith & Nephew from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 1st. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Smith & Nephew in a research note on Thursday, November 1st. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Smith & Nephew currently has an average rating of “Hold” and an average price target of $42.00.
NYSE:SNN opened at $38.44 on Tuesday. Smith & Nephew has a 12 month low of $32.22 and a 12 month high of $40.78. The company has a quick ratio of 1.15, a current ratio of 2.10 and a debt-to-equity ratio of 0.27. The company has a market cap of $17.58 billion, a price-to-earnings ratio of 19.03, a PEG ratio of 3.07 and a beta of 0.48.
Several institutional investors have recently modified their holdings of the company. Nuance Investments LLC boosted its holdings in shares of Smith & Nephew by 30.5% during the 3rd quarter. Nuance Investments LLC now owns 2,794,889 shares of the medical equipment provider’s stock worth $103,722,000 after purchasing an additional 653,488 shares during the last quarter. Iridian Asset Management LLC CT acquired a new position in shares of Smith & Nephew during the 4th quarter worth approximately $100,574,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Smith & Nephew by 31.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 889,934 shares of the medical equipment provider’s stock worth $33,008,000 after purchasing an additional 211,919 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Smith & Nephew by 1.0% during the 2nd quarter. Northern Trust Corp now owns 689,297 shares of the medical equipment provider’s stock worth $25,870,000 after purchasing an additional 6,530 shares during the last quarter. Finally, Crossmark Global Holdings Inc. lifted its holdings in Smith & Nephew by 4.7% in the third quarter. Crossmark Global Holdings Inc. now owns 374,014 shares of the medical equipment provider’s stock valued at $13,872,000 after acquiring an additional 16,923 shares during the last quarter. Institutional investors and hedge funds own 8.92% of the company’s stock.
Smith & Nephew Company Profile
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
See Also: Short Selling Stocks and Day Traders
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.